Further evidence that antithrombotic therapy is beneficial with streptokinase: improved early ST resolution and late patency with enoxaparin

[1] Folsom AR, Wu KK, Conlan MG. Fibrinogen and cardiovascular risk in the atherosclerosis risk in communities (ARIC) study. In: Ernst E et al., eds. Fibrinogen a New Cardiovascular Risk Factor 1992, pp. 124–9. Blackwell-MZV. [2] Barker et al. Relation of fetal and infant growth to plasma fibrinogen in adult live. Br Med J 1992; 304: 148–52. [3] Tsutsumi et al. Association between job characteristics and plasma fibrinogen in a normal working population. J Epidemiol Community Health 1999; 53: 348–54. [4] Lacoviello L et al. Genes encoding fibrinogen and cardiovascular risk. Hypertension 2001; 38: 1199–203. [5] Humphries SE et al. European Atherosclerosis Research Study; genotype at the fibrinogen locus (G-455-Abeta gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe. Arterioscler Thromb Vasc Biol 1992; 15: 96–104. [6] Folsom AR et al. Beta fibrinogen gene-455G/A polymorphism and coronary heart disease incidence: ARIC Study. Ann Epidemiol 2001; 11: 166–70. [7] Nishiuma S et al. Genetic variation in the promotor region of the beta-fibrinogen gene is associated with ischemic stroke in a Japanese population. Blood Coagul Fibrinolysis 1998; 9: 373–9. [8] Gardemann A et al. Positive association of the beta fibrinogen H1/H2 gene variation to basal fibrinogen levels but not to coronary artery disease and myocardial infarction. Thromb Haemost, 1997; 77: 1120–6. [9] Droggen CJ et al. Interaction of coagulation defects and cardiovascular risk factors. Circulation 1998; 97: 1037–41. [10] Kohler HP et al. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med ; 342: 1792–801. [11] Bottinger C et al. HPA-1 and HPA-3 polymorphisms of platelet fibrinogen receptor and coronary artery disease and myocardial infarction. Thromb Haemost 2000; 83: 559–62. [12] Laule M et al. A1/A2 polymorphism of glycoprotein 3a and association with excess procedural risk for coronary catheter interventions; a case controlled study. Lancet 1999; 353: 708–12.